About Sputnik V & Sputnik Light
PRESENTATION ON SPUTNIK V & SPUTNIK LIGHT
READ MORE - HERE
ABOUT SPUTNIK V
Sputnik V is the world's first registered vaccine based on a well-studied human adenovirus vector platform. It has been approved for use in 71 countries with a total population of 4 billion people. The vaccine’s efficacy is 97.6%, based on the analysis of data on the incidence of coronavirus among Russians vaccinated with both vaccine components between December 5, 2020 and March 31, 2021.
Sputnik V is effective against new strains of coronavirus, . The vaccine produces protective neutralising antibody titres against new strains, including Alpha B.1.1.7 (first identified in the UK), Beta B.1.351 (first identified in South Africa), Gamma P.1 (first identified in Brazil), Delta B.1.617.2 and B.1.617.3 (first identified in India) and variants B.1.1.141 and B.1.1.317 with mutations in the receptor-binding domain (RBD) identified in Moscow.
Preliminary laboratory study by the Gamaleya Center shows that Sputnik V demonstrates high virus neutralizing activity against Omicron variant and is expected to protect against severe cases and hospitalizations.
ABOUT SPUTNIK LIGHT
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus. ! 80% proven efficacy against infection, higher than that of most two-shot vaccines, the efficacy against hospitalization and severe disease is even higher.
Sputnik Light is also a leading booster shot for people previously infected with COVID-19 and for revaccinations after Sputnik V or other vaccines.
Sputnik Light as a stand-alone vaccine is highly effective against Delta and other mutations: efficacy against infection by Delta - 70%, efficacy in the age group below 60 - 75%. Sputnik Light efficacy as a booster will be close to that of two shots of Sputnik V against Delta: effective against infection - over 83%, effective against hospitalization - over 94%. Sputnik Light as a booster increases virus neutralizing activity against Omicron variant considerably developed neutralizing antibodies against Omicron variant.
